Therapeutic targets for glaucoma

Drugs of the Future

Volumn 35, Issue 7, 2010, Pages 585-592

  Sorbera, L A ^a   Aravamudan, J ^a   Dulsat, C ^a   Rosa, E ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AC 262271; ACETYLCHOLINESTERASE; ACTIN; ADENOSINE A1 RECEPTOR; ADENOSINE TRIPHOSPHATE; APRACLONIDINE; AR 102; AR 12286; ATS 907; BEFUNOLOL; BETA 1 ADRENERGIC RECEPTOR; BRIMONIDINE; BRINZOLAMIDE; BUNAZOSIN; CANNABINOID 1 RECEPTOR; CARTEOLOL; CHOLINESTERASE; CXB 006; DAPIPRAZOLE; DE 104; FORSKOLIN; INO 8875; INS 115644; INS 117548; K 115; KR 262271; KR 31378; LATANOPROST; LOMERIZINE; METIPRANOLOL; MOXAVERINE; NIPRADILOL; OT 730; PF 04475270; PHYSOSTIGMINE SALICYLATE; PILOCARPINE; PROSTANOID RECEPTOR; TAPRENEPAG ISOPROPYL; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y 39983;

AQUEOUS HUMOR; BLINDNESS; DRUG TARGETING; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NERVE FIBER; REVIEW; VISUAL IMPAIRMENT;

EID: 84952981761     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.07.1520867     Document Type: Review

References (64)

1. SM Disease Briefings: Glaucoma (online publication). Updated 2010.
2. Caprioll, J., Coleman, A.L. Blood flow in glaucoma discussion. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010, 149(5): 704-12.
3. Ray, K., Mookherjee, S. Molecular complexity of primary open angle glaucoma: current concepts. J Genet 2009, 88(4): 451-67.
4. Costagliola, C., dell'Omo, R., Romano, M.R., Rinaldi, M., Zeppa, L., Parmeggiani, F. Pharmacotherapy of Intraocular pressure: Part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother 2009, 10(16): 2663-77.
5. Mackenzie, P., Cioffi, G. How does lowering of intraocular pressure protect the optic nerve? Surv Ophthalmol 2008, 53(Suppl. 1): S39-43.
6. Quigley, H.A., Broman, A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006, 90(3): 262-7.
7. Cedrone, C., Mancino, R., Cerulli, A., Cesareo, M., Nucci, C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res 2008, 173: 3-14.
8. Salim, S., Shields, M.B. Glaucoma and systemic diseases. Surv Ophthalmol 2010, 55(1): 64-77.
9. Sultan, M.B., Mansberger, S.L., Lee, P.P. Understanding the importance of IOP variables in glaucoma: A systematic review. Surv Ophthalmol 2009, 54(6): 643-62.
10. Weinreb, R.N., Khaw, P.T. Primary open-angle glaucoma. Lancet 2004, 363(9422): 1711-20.
11. Challa, P. Glaucoma genetics. Int Ophthalmol Clin 2008, 48(4): 73-94.
12. Kass, M.A., Gordon, M.O., Gao, F. et al. Delaying treatment of ocular hypertension: The ocular hypertension treatment study. Arch Ophthalmol 2010, 128(3): 276-87.
13. Costagliola, C., dell'Omo, R., Romano, M.R., Rinaldi, M., Zeppa, L., Parmeggiani, F. Pharmacotherapy of intraocular pressure - Part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009, 10(17): 2859-70.
14. Sakamoto, K., Ohki, K., Saito, M., Nakahara, T., Ishii, K. Histological protection by donepezil against neurodegeneration induced by ischemia-reperfusion in the rat retina. J Pharmacol Sci 2010, 112(3): 327-35.
15. Patil, P.N., Stearns, R. Mechanism of vascular relaxation by cholinomimetic drugs with special reference to pilocarpine and arecoline. J Ocul Pharmacol Ther 2002, 18(1): 25-34.
16. Estermann, S., Daepp, G.C., Cattapan-Ludewig, K., Berkhoff, M., Frueh, B.E., Goldblum, D. Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. J Ocul Pharmacol Ther 2006, 22(1): 62-7.
17. Goldblum, D., Garweg, J.G., Böhnke, M. Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. J Ocul Pharmacol Ther 2000, 16(1): 29-35.
18. Zhuo, Y.H., He, Y., Leung, K.W., Hou, F., Li, Y.Q., Chai, F., Ge, J. Dexamethasone disrupts intercellular junction formation and cytoskeleton organization in human trabecular meshwork cells. Mol Vis 2010, 16: 61-71.
19. Tian, B., Gabelt, B.T., Geiger, B., Kaufman, P.L. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 2009, 88(4): 713-7.
20. Read, A.T., Chan, D.W., Ethier, C.R. Actin structure in the outflow tract of normal and glaucomatous eyes. Exp Eye Res 2006, 82(6): 974-85.
21. Chen, L., Lukas, T.J., Hernandez, M.R. Hydrostatic pressure-dependent changes in cyclic AMP signaling in optic nerve head astrocytes from Caucasian and African American donors. Mol Vis 2009, 15: 1664-72.
22. Kim, N., Crosson, C., Supuran, C., McCauley, T., Southan, G., Baumgartner, R., McVicar, W. INO-8875, an adenosine A1 agonist, in development for open-angle glaucoma reduces IOP in three rabbit models. Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 3-7, Fort Lauderdale) 2009, Abst 4061-A223.
23. Zhang, X., Wang, N., Schroeder, A., Erickson, K.A. Expression of adenylate cyclase subtypes II and IV in the human outflow pathway. Invest Ophthalmol Vis Sci 2000, 41(5): 998-1005.
24. Sakanaka, K., Kawazu, K., Tomonari, M. et al. Ocular pharmacokinetic/ pharmacodynamic modeling for multiple anti-glaucoma drugs. Biol Pharm Bull 2008, 31(8): 1590-5.
25. Hara, H., Ichikawa, M., Oku, H., Shimazawa, M., Araie, M. Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: Effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev 2005, 23(1): 43-56.
26. Gilsbach, R., Röser, C., Beetz, N. et al. Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells. Mol Pharmacol 2009, 75(5): 1160-70.
27. Dong, C.J., Guo, Y., Agey, P., Wheeler, L., Hare, W.A. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008, 49(10): 4515-22.
28. Savolainen, J., Rautio, J., Razzetti, R., Järvinen, T. A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits. J Pharm Pharmacol 2003, 55(6): 789-94.
29. Croxtall, J.D., Scott, L.J. Brinzolamide/timolol: In open-angle glaucoma and ocular hypertension. Drugs Aging 2009, 26(5): 437-46.
30. Curran, M.P., Orman, J.S. Bimatoprost/timolol: A review of its use in glaucoma and ocular hypertension. Drugs Aging 2009, 26(2): 169-84.
31. McKinnon, S.J., Goldberg, L.D., Peeples, P., Walt, J.G., Bramley, T.J. Current management of glaucoma and the need for complete therapy. Am J Manag Care 2008, 14(1, Suppl.): S20-7.
32. Selt, M., Bartlett, C.A., Harvey, A.R., Dunlop, S.A., Fitzgerald, M. Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. Brain Res Bull 2010, 81(4-5): 467-71.
33. Wang, R.F., Gagliuso, D.J., Podos, S.M. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys. J Glaucoma 2008, 17(1): 73-8.
34. Lesk, M.R., Wajszilber, M., Deschenes, M.C. The effects of systemic medications on ocular blood flow. Can J Ophthalmol 2008, 43(3): 351-5.
35. Pemp, B., Garhofer, G., Lasta, M., Schmidl, D., Wolzt, M., Schmetterer, L. The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects. Acta Ophthalmol 2010, Epub ahead of print.
36. Resch, H., Weigert, G., Karl, K., Pemp, B., Garhofer, G., Schmetterer, L. Effect of systemic moxaverine on ocular blood flow in humans. Acta Ophthalmol 2008, 87(7): 731-5.
37. Hariton, C. Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol 1994, 258(1-2): 85-94.
38. Svízenská, I, Dubový, P., Sulcová, A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review. Pharmacol Biochem Behav 2008, 90(4): 501-11.
39. Singh, J., Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands: Current status. Methods Find Exp Clin Pharmacol 2006, 28(3): 177-83.
40. Thakur, G.A., Nikas, S.P., Makriyannis, A. CB1 cannabinoid receptor ligands. Mini Rev Med Chem 2005, 5(7): 631-40.
41. Gilmour, K.M. Perspectives on carbonic anhydrase. Comp Biochem Physiol A Mol Integr Physiol 2010, Epub ahead of print.
42. Moss, A.M., Harris, A., Siesky, B., Rusia, D., Williamson, K.M., Shoshani, Y. Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients. Clin Ophthalmol 2010, 4: 233-41.
43. Gugleta, K. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension. Curr Med Res Opin 2010, 26(6): 1255-67.
44. Choi, A., Choi, J.S., Yoon, Y.J., Kim, K.A., Joo, C.K. KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci 2009, 109(4): 511-7.
45. Konno, T., Uchibori, T., Nagai, A., Kogi, K., Nakahata, N. 2-(1-Hexyn-1-yl)adenosine-induced intraocular hypertension is mediated via K+ channel opening through adenosine A2A receptor in rabbits. Eur J Pharmacol 2005, 518(2-3): 203-11.
46. Ettaiche, M., Heurteaux, C., Blondeau, N., Borsotto, M., Tinel, N., Lazdunski, M. ATP-sensitive potassium channels (K(ATP)) in retina: A key role for delayed ischemic tolerance. Brain Res 2001, 890(1): 118-29.
47. Zhou, W., Zhu, X., Zhu, L. et al. Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons. Cell Mol Neurobiol 2008, 28(2): 263-75.
48. Duncan, C., Collison, D.J. Role of the non-neuronal cholinergic system in the eye: A review. Life Sci 2003, 72(18-19): 2013-9.
49. Collison, D.J., Coleman, R.A., James, R.S., Carey, J., Duncan, G. Characterization of muscarinic receptors in human lens cells by pharmacologic and molecular techniques. Invest Ophthalmol Vis Sci 2000, 41(9): 2633-41.
50. Kang, K.D., Andrade da Costa, B.L., Osborne, N.N. Stimulation of prostaglandin EP2 receptors on RGC-5 cells in culture blunts the negative effect of serum withdrawal. Neurochem Res 2010, 35(5): 820-9.
51. Prasanna, G., Fortner, J., Xiang, C. et al. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp Eye Res 2009, 89(5): 608-17.
52. Aguirre, S.A., Huang, W., Prasanna, G., Jessen, B. Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist. Toxicol Pathol 2009, 37(7): 911-20.
53. Sharif, N.A., Williams, G.W., Crider, J.Y., Xu, S.X., Davis, T.L. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes. J Ocul Pharmacol Ther 2004, 20(6): 489-508.
54. Aihara, M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2010, 4: 163-70.
55. Woodward, D.F., Liang, Y., Krauss, A.H. Prostamides (prostaglondin- ethanolamides) and their pharmacology. Br J Pharmacol 2008, 153(3): 410-9.
56. Hahmann, C., Schroeter, T. Rho-kinase inhibitors as therapeutics: From pan inhibition to isoform selectivity. Cell Mol Life Sci 2010, 67(2): 171-7.
57. Davis, R.L., Kahraman, M., Prins, T.J. et al. Benzothiophene containing Rho kinase inhibitors: Efficacy in on animal model of glaucoma. Bioorg Med Chem Lett 2010, 20(11): 3361-6.
58. Henderson, A.J., Hadden, M., Guo, C. et al. 2,3-Diaminopyrazines as rho kinase inhibitors. Bioorg Med Chem Lett 2010, 20(3): 1137-40.
59. Nien, C.Y., Chen, Y.C., Kuo, C.C. et al. 5-Amino-2-aroylquinolines as high-ly potent tubulin polymerization inhibitors. J Med Chem 2010, 53(5): 2309-13.
60. Schlunck, G., Han, H., Wecker, T.., Kampik, D., Meyer-ter-Vehn, T., Grehn, F. Substrate rigidity modulates cell matrix interactions and protein expression in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2008, 49(1): 262-9.
61. Balaratnasingam, C., Morgan, W.H., Bass, L., Matich, G., Cringle, S.J., Yu, D.Y. Axonal transport and cytoskeletal changes in the laminar regions after elevated intraocular pressure. Invest Ophthalmol Vis Sci 2007, 48(8): 3632-44.
62. Sugimoto, Y., Mochizuki, H., Okumichi, H., Takumida, M., Takamatsu, M., Kawamata, S., Kiuchi, Y. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010, Epub ahead of print.
63. Horsley, M.B., Kahook, M.Y. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010, 21(2): 112-7.
64. Iwabe, S., Lamas, M., Vásquez Pélaez, C.G., Carrasco, F.G. Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients. Curr Eye Res 2010, 35(4): 287-94.